Shire wins FDA approval for potential blockbuster rare disease drug

The FDA has approved a potential blockbuster rare disease drug developed by Shire plc, which is set to be absorbed by Takeda Pharmaceuticals next year. The drug, Takhzyro, treats a rare and potentially life-threatening genetic disease called hereditary angioedema, or HAE, which leads to episodes of swelling in the limbs, abdomen and airway. Shire's (Nasdaq: SHPG) Phase 3 studies showed that patients taking the injectable drug every two weeks expe rienced an 87 percent reduction in attacks. Analysts…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news